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can help to understand common underlying pathways, and the use of drugs targeted 
to associated symptoms.
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Objectives: To quantify men’s preferences and willingness to pay for attributes 
of medications to treat LUTS/BPH using a DCE. MethOds: An online DCE was 
conducted with men in the UK aged ≥ 45 years with a self-reported International 
Prostate Symptom Score (IPSS) ≥ 8. Men were asked to consider different scenarios 
associated with moderate-to-severe LUTS, and then choose between two medical 
alternatives and a no-treatment option, according to seven attributes: day-time 
urinary frequency, night-time urinary frequency, urgency, sexual and non-sexual 
side effects, number of tablets/day and cost/month. These attributes were identi-
fied from a literature review and online discussion groups (ODGs). Men’s marginal 
willingness to pay (MWTP) and 95% confidence intervals for improvements in each 
attribute were calculated. Please see a separate meeting abstract for more informa-
tion on the ODGs (Ikenwilo, et al). Results: The DCE survey was conducted 19–26 
March 2014. 5212 individuals were invited to participate: 1097 opened the hyperlink, 
586 were ineligible or excluded because the quota was full, and 247 completed the 
final survey used for this analysis. The mean age was 62.3 years and the mean IPSS 
was 15.7 (standard deviation 6.0). MWTP was £23.95/month and £25.42/month for 
an improvement from urge incontinence to moderate urgency or mild urgency, 
respectively; £5.80/month for one less night-time urination, and £1.30/month for 
one less day-time urination. Sexual side effects reduced MWTP by £29.70/month 
for erectile dysfunction, £18.37/month for “decreased sexual desire”, and £16.92/
month for “no fluid during ejaculation”. Non-sexual side effects reduced MWTP by 
£17.25/month for dizziness and £16.75/month for headaches. Neither dry mouth nor 
the number of tablets/day significantly affected MWTP.cOnclusiOns: Improving 
urgency is perceived as the most important benefit of medication to men with LUTS/
BPH; improving frequency is also valued. The perceived value of a medication is 
reduced by sexual and non-sexual side effects. 
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Objectives: “Off-label” is defined by the Turkish Ministry of Health (MoH) as 
the use of licensed pharmaceutical products in doses outside the scope of the 
registered indication and the use of unlicensed medicinal products that are 
imported for the purpose of individual treatment. Off-label use of medications is 
extremely common especially in oncology. The aim of the study is to evaluate the 
usage of off-label or unlicensed medicines in urologic cancers for understand-
ing of Turkey’s perspective within this area of health care provisions. MethOds: 
This study involved patients (n= 105) with metastatic bladder CA who received 
paklitaxel or other medicine application off-label, (n= 194) with metastatic renal 
cell CA who received sorafenib, sunitinib or other medicine application off-label, 
(n= 44) with metastatic testis cancer who received paklitaxel, gemsitabin or other 
medicine application off-label in Turkey. A computer search was performed using 
the TITCK’s (Turkish Drug and Medical Devices Institution) database. The patient 
base was searched for off-label medicine applications between 1st May 2008 to 
1st May 2011. Results: The data obtained from TITCK’s database showed that 86, 
136, and 44 applications for off-label metastatic bladder CA medicine, metastatic 
renal cell CA and metastatic testis CA medicine usage, respectively. Ninety five 
(90.47%) of all off-label medicine usage applications for metastatic bladder CA, one 
hundred twenty two (62.88%) for metastatic renal cell CA and thirty nine (88.63%) 
for metastatic testis CA were approved. University hospitals were created the vast 
majority of applications (79.89%) for metastatic bladder CA, (64.76%) for metastatic 
bladder CA and (79.89%) for metastatic bladder CA. The most preferable off-label 
drug medications for bladder CA, renal CA and testis CA were paklitaksel (84.04%), 
sorafenib (68.42%) and paklitaksel (43.24%), respectively. cOnclusiOns: Off-label 
urology medicine use is rising in Turkey. If off-label use increasing parallel to the 
off-label urology medicines, it is needed to define new pathways to evaluate the 
applications.
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Objectives: To assess health-related quality of life (HRQOL) and subjective happiness 
of men with lower urinary tract symptoms associated with benign prostatic hyper-
plasia (BPH/LUTS). MethOds: In 2014 a multicenter cross-sectional questionnaire 
survey was conducted in Hungary. Inclusion criteria were diagnosis of BPH/LUTS at 
least 12 months before the study and patient had never been undergone any prostate 
surgery. HRQOL was assessed indirectly by the EQ-5D and visual analogue scale (EQ 
VAS) and directly by matching indifference time trade-off (TTO) where patients’ sub-
jective life expectancy was applied as time frame. Subjective happiness was measured 
on a 10-cm-long visual analogue scale. Results: In total 64 men completed the 
questionnaire, mean age and disease duration were 70.8±8.8 years and 6.9±6.5 years, 
respectively. At the time of the survey, 75% of the patients received alpha-blockers 
(AB), 11% were treated by 5-alpha-reductase inhibitors (5ARI), and 11% by combina-
tion therapy (AB+5ARI). Median EQ-5D, EQ VAS, TTO and happiness scores were 0.85, 
70, 0.73 and 6.5, respectively. Utilities assessed by EQ-5D were found significantly 
higher compared to those elicited by TTO (p< 0.001). Mean utilities decreased with 
clinical severity measured with EQ-5D (mild: 0.90±0.1, moderate to severe: 0.79±0.2, 
p= 0.046) whereas increased when assessed with TTO (mild: 0.46±0.3, moderate to 
severe: 0.63±0.3, p= 0.336). Patients with moderate to severe disease reported signifi-
cantly lower happiness scores than those with mild disease (5.85±2.2 and 7.02±2.3, 
p= 0.044). Subjective happiness correlated moderately with EQ VAS (rs= 0.64, p< 0.001) 
but only weakly with EQ-5D (rs= 0.28, p= 0.029). cOnclusiOns: BPH/LUTS patients 
experience notable reduction in their HRQOL and subjective happiness measured by 
any of the applied outcome measures. Utilities for BPH/LUTS ranged from 0.46 to 0.90 
depending on clinical severity and assessment method. Considerable discrepancy was 
found between utilities elicited by EQ-5D and TTO that raises concerns about which 
method is feasible to use for utility evaluation in BPH/LUTS.
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Objectives: To understand men’s attitudes, preferences and values for LUTS/BPH 
management and its impact on quality of life (QoL) using a MMA. MethOds: The 
innovative MMA approach combined qualitative (online discussion groups [ODG]) 
and quantitative methods (discrete choice experiment [DCE]). ODGs and a self-
administered online DCE survey were conducted with men in the UK aged ≥ 45 
years with an International Prostate Symptom Score (IPSS) ≥ 8. A series of five asyn-
chronous ODGs (or bulletin boards) were live for 5 days (moderated by the research 
team). The ODGs collected information about men’s experiences of LUTS/BPH and 
its impact on their QoL; data were analysed using an inductive thematic analysis. 
A literature review informed the ODG design, and both informed the DCE design. 
The DCE survey elicited men’s preferences for LUTS/BPH medical management. 
Please see a separate meeting abstract for more information on the DCE (Ikenwilo, 
et al). Results: 48 men were invited to the ODGs; 22 participated and had a mean 
age of 59.8 years and mean IPSS of 16.4 (standard deviation 7.1). The ODGs found that 
LUTS/BPH affects how men organise their day at work and at home, and prevents 
men from leading their preferred daily activities. Symptoms most adversely affect-
ing QoL were urgency (especially urge incontinence) and day-time and night-time 
urinary frequency. There appears to be a lack of awareness about LUTS amongst 
the men: many had not discussed LUTS with their doctor, family or friends, and 
were unaware that LUTS/BPH is treatable. The DCE informs that men are willing to 
pay at least £23.95/month to improve urgency, and £29.70/month to avoid erectile 
dysfunction. cOnclusiOns: This is the first MMA to evaluate men’s preferences in 
LUTS/BPH. The ODG and DCE results together expand our understanding of men’s 
attitudes toward the management of LUTS/BPH.
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Objectives: This study assessed the prevalence of symptoms, and symptom clusters 
in a sample of dialysis patients in Uruguay. MethOds: A longitudinal study aimed 
to assess HRQL in hemo (HD) and peritoneal dialysis patients (PD) was conducted 
in thirteen centers in Uruguay. Data of the first assessment was included here. The 
12 items of the KDQOL-36 Symptom Subscale were analyzed for symptom preva-
lence. For cluster analyses the ICLUST procedure was followed, using an algorithm 
to hierarchically cluster items to form composite scales. Alpha, the mean split half 
correlation, and beta, the worst split half correlation, are estimates of the reliabil-
ity and general factor saturation of the test. Clusters are combined if coefficients 
increase in the new cluster. Results: Of a total of 751 patients, 486 accepted to 
participate and completed the forms (64.7%), with mean age 60.5 years, SD: 15.5), 
211 (43.4%) were women; 407 (83.7%) were HD, and 79 (16.3%) were PD patients. 
Most prevalent symptoms were muscle sores (59.0%); cramps (57.5%); “washed out” 
(50.9%), dry skin (48.5%), and itchy skin (43.8%). Five clusters of symptoms were 
identified; “cutaneous” (itchy and dry skin, α  .68), ”cardiac” (chest pain and short-
ness of breath, α  .69), ”digestive” (nausea and lack of appetite, α .62), ”neurophatic” 
(numbness and cramps, α  .50), ”energy” (“washed out”, faintness, α  .59). A second 
block called “locomotive” included neuropathic plus muscle sores (α  .64), and a third 
of “neurological symptoms” included locomotive plus energy (α .70). Cutaneous 
symptoms remained as a separated cluster. Cronbach alpha of the total Symptom 
Scale was .93. cOnclusiOns: Dialysis patients experience a high number of 
symptoms. The study of clusters identified 5 groups of symptoms; cutaneous, cardiac, 
neuropathic, digestive and lack of energy. More complex associations included neu-
rological, digestive and cardiac complaints. The identification of symptom clusters 
